← Back to Search

Other

Regadenoson for COVID-19

Phase 1 & 2
Waitlist Available
Led By Christine L Lau, MD, MBA
Research Sponsored by University of Maryland, Baltimore
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days
Awards & highlights

Study Summary

This trial is investigating whether tocilizumab, an immunosuppressive drug that is already approved to treat other conditions, can help treat patients with moderate to severe COVID-19 by reducing the severity of their cytokine storms.

Eligible Conditions
  • COVID-19
  • Coronavirus
  • Pneumonia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of patients alive and free of respiratory failure through the 30-day trial.
Secondary outcome measures
Change of the levels of MMP-2 and MMP-9 prior, during and post drug infusion.
Change of the levels of the inflammatory cytokines prior, during and post drug infusion.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Active ArmExperimental Treatment1 Intervention
Regadenoson will be given intravenously as 5 ug/kg loading dose (up to 400 mg/patient) over 30 mins (to avoid unpleasant side effects sometimes associated with the rapid bolus injection of Regadenoson), followed by a continuous slow infusion (1.44micrograms/kg/hour) with the use of a pediatric infusion pump for 6 hours.
Group II: Control ArmPlacebo Group1 Intervention
The same volume of saline will be given intravenously for 30 mins followed by a continuous infusion for 6 hours.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Regadenoson
2012
Completed Phase 4
~5300

Find a Location

Who is running the clinical trial?

University of Maryland, BaltimoreLead Sponsor
687 Previous Clinical Trials
374,641 Total Patients Enrolled
4 Trials studying COVID-19
316 Patients Enrolled for COVID-19
Christine L Lau, MD, MBAPrincipal InvestigatorUniversity of Maryland, Baltimore

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any remaining opportunities for individuals to join this research endeavor?

"Affirmative. Clinicaltrials.gov reveals that this medical trial, which was first published on May 6th 2021 is currently recruiting patients for the study. A total of 40 participants need to be enlisted from a single site."

Answered by AI

Is this study the pioneering effort in its field?

"Since 2014, Regadenoson has been subject to ongoing clinical trials. The first such study was sponsored by Astellas Scientific & Medical Affairs, Inc., and involved 300 patients. This initial research resulted in the drug receiving its Phase 4 approval from regulatory bodies. At present, 6 studies are underway across 6 cities and nations worldwide."

Answered by AI

How many participants is the clinical trial accommodating?

"Affirmative. Clinicaltrials.gov's data verifies that this medical research, which was first shared on May 6th 2021, is actively recruiting. 40 individuals need to be recruited from 1 clinical site in total."

Answered by AI

What prior experimentation has been done with Regadenoson?

"As of now, 6 active clinical studies are investigating Regadenoson but none of them have progressed to the final stage. 12 distinct locations across the country are currently running these trials and several of them can be found in Houston, Texas."

Answered by AI
Recent research and studies
The American Journal of PathologyJournal
An Extensive Invasive Intracranial Human Glioblastoma Xenograft Model
Zhao, Yunge, Aizhen Xiao, Charles G. diPierro, Joan E. Carpenter, Rana Abdel-Fattah, Gerard T. Redpath, Maria-Beatriz S. Lopes, and Isa M. Hussaini. 2010. “An Extensive Invasive Intracranial Human Glioblastoma Xenograft Model”. The American Journal of Pathology. Elsevier BV. doi:10.2353/ajpath.2010.090571.
The Journal of Heart and Lung TransplantationJournal
Adenosine A2A Receptor Agonist (regadenoson) in Human Lung Transplantation
Lau, Christine L., Jared P. Beller, Joshua A. Boys, Yunge Zhao, Jennifer Phillips, Michael Cosner, Mark R. Conaway, et al.. 2020. “Adenosine A2A Receptor Agonist (regadenoson) in Human Lung Transplantation”. The Journal of Heart and Lung Transplantation. Elsevier BV. doi:10.1016/j.healun.2020.02.003.
Blood AdvancesJournal
Randomized Phase 2 Trial of Regadenoson for Treatment of Acute Vaso-occlusive Crises in Sickle Cell Disease
Field, Joshua J., Elaine Majerus, Victor R. Gordeuk, Michel Gowhari, Carolyn Hoppe, Matthew M. Heeney, Maureen Achebe, et al.. 2017. “Randomized Phase 2 Trial of Regadenoson for Treatment of Acute Vaso-occlusive Crises in Sickle Cell Disease”. Blood Advances. American Society of Hematology. doi:10.1182/bloodadvances.2017009613.
American Journal of Physiology-Lung Cellular and Molecular PhysiologyJournal
Depletion of Tissue Plasminogen Activator Attenuates Lung Ischemia-reperfusion Injury via Inhibition of Neutrophil Extravasation
Zhao, Yunge, Ashish K. Sharma, Damien J. LaPar, Irving L. Kron, Gorav Ailawadi, Yuan Liu, David R. Jones, Victor E. Laubach, and Christine L. Lau. 2011. “Depletion of Tissue Plasminogen Activator Attenuates Lung Ischemia-reperfusion Injury via Inhibition of Neutrophil Extravasation”. American Journal of Physiology-lung Cellular and Molecular Physiology. American Physiological Society. doi:10.1152/ajplung.00227.2010.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top